deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04882072

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis

Sponsor: Janssen Pharmaceutical K.K.

Conditions Takayasu Arteritis
Interventions Glucorticoid Taper Regimen Placebo Ustekinumab
Updated 30 times since 2021 Last updated: Apr 25, 2025 Started: Sep 15, 2021 Primary completion: May 25, 2023 Completion: May 25, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to difficulties in enrollment and ongoing feasibility issues

Other terminated trials from Janssen Pharmaceutical K.K.

See all terminations from Janssen Pharmaceutical K.K.

A PHASE3 clinical study on Takayasu Arteritis, this trial is terminated or withdrawn. The trial is conducted by Janssen Pharmaceutical K.K. and has accumulated 30 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. May 2025 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Mar 2025 — May 2025 [monthly]

    Terminated PHASE3

  4. Feb 2025 — Mar 2025 [monthly]

    Terminated PHASE3

  5. Jan 2025 — Feb 2025 [monthly]

    Terminated PHASE3

▶ Show 25 earlier versions

  1. Dec 2024 — Jan 2025 [monthly]

    Terminated PHASE3

  2. Sep 2024 — Dec 2024 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jul 2023 — Sep 2023 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  6. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  7. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  10. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  11. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  12. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  13. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  14. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  15. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  16. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  17. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  18. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  19. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  20. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  21. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  22. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  23. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  24. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  25. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceutical K.K.
Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bunkyō City, Japan , Chiba, Japan , Fukuoka, Japan , Hamamatsu, Japan , Iruma-gun, Japan , Kita Gun, Japan , Kobe, Japan , Kyoto, Japan , Matsuyama, Japan , Nagoya, Japan and 14 more locations